Creams, Screams, and Measles

Pediatric dermatology has evolved significantly with the introduction of new topical treatments for atopic dermatitis, including Opzelura, Zoryve, and Vtama. These agents offer improved efficacy and tolerability compared to traditional steroids and calcineurin inhibitors, though clinicians must carefully balance potency against systemic absorption risks, particularly in younger patients. Effective management often involves personalized pulsing strategies and clear communication with families regarding treatment goals. Beyond dermatology, the conversation highlights the critical need for recognizing measles symptoms—such as the characteristic top-down rash and transient Koplik spots—and understanding the severe, long-term risks of subacute sclerosing panencephalitis (SSPE). Dr. Sheila Fallon Friedlander, a pediatric dermatologist, emphasizes that while clinical advancements provide better outcomes, maintaining high vaccination rates remains the primary defense against preventable, life-altering complications like SSPE.